剑桥髓鞘修复中心试验二(CCMR Two):二甲双胍联合氯马斯汀促进复发缓解型多发性硬化患者髓鞘再生的2a期随机双盲安慰剂对照临床试验方案
CCMR Two是一项2a期随机双盲安慰剂对照试验方案,计划招募70例已接受疾病修饰治疗且至少一眼存在慢性稳定视神经病变的复发缓解型多发性硬化患者,1:1随机接受二甲双胍联合氯马斯汀或匹配安慰剂治疗24周,主要终点为基线至第26周全视野视觉诱发电位P100潜伏期变化,旨在评估联合治疗促进髓鞘再生的疗效。
要点
- 纳入标准要求至少一眼P100潜伏期≥118 ms且近2年无急性视神经炎病史。
- 主要终点为基线至第26周全视野VEP P100潜伏期变化,计划样本量70例。
- 该样本量有80%把握度检测两组间VEP P100潜伏期3 ms的降低。
核心结论
- 本试验旨在评估二甲双胍联合氯马斯汀在复发缓解型多发性硬化患者中促进髓鞘再生的疗效。
- 作者预期在单中心试验可行的样本量内检测到髓鞘再生的结构和功能后果。
研究设计与样本
- 2a期随机双盲安慰剂对照临床试验方案,参与者按1:1随机分配至二甲双胍联合氯马斯汀组或匹配安慰剂组,治疗随访24周。
- 计划招募70例复发缓解型多发性硬化患者,所有参与者须稳定接受疾病修饰治疗,且至少一眼存在慢性稳定视神经病变(定义为视觉诱发电位P100潜伏期≥118 ms,且近2年无急性视神经炎病史)。
- 主要终点为基线至第26周全视野视觉诱发电位P100潜伏期的变化。
- 该样本量有80%把握度检测两组间VEP P100潜伏期3 ms的降低。
- 次要终点包括多焦VEP变化以及按病灶位置和组织特异性基线病灶MTR值分层的病灶磁化转移率变化。
关键数值与推荐
- 慢性稳定视神经病变定义为P100潜伏期≥118 ms且近2年无急性视神经炎病史。
- 主要终点为基线至第26周全视野VEP P100潜伏期变化。
- 计划样本量70例,有80%把握度检测VEP P100潜伏期降低3 ms。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS. METHODS: Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24 weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP) ≥ 118 ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3 ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values. DISCUSSION: We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT05131828, prior to participant enrolment.
引用
- Riboni-Verri G, McMurran CE, Mukherjee T, et al. The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy. Trials. 2025. PMID: 41361285. doi:10.1186/s13063-025-09254-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。